Home › Calculator › RLYB Dividend Calculator 2026
RLYB Dividend DRIP Calculator 2026
12.63% YieldHealthcareRallybio Corporation · NASDAQ
Price: $15.83 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When RLYB pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your RLYB snowball 📈
$10,000 in RLYB → $32.9K in 10 years · $307.19/month
About Rallybio Corporation (RLYB) — Dividend Analysis 2026
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Compare RLYB with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full RLYB DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open RLYB position with:
🌍 RLYB Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold RLYB.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 12.63% | 9.83% | $1,263 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 10.74% | 7.94% | $1,074 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 10.10% | 7.30% | $1,010 / yr |
| 🇬🇧 UK ISA | 0% | 12.63% | 9.83% | $1,263 / yr |
| 🇬🇧 UK Taxable | 8.75% | 11.52% | 8.72% | $1,152 / yr |
| 🇨🇦 TFSA | 0% | 12.63% | 9.83% | $1,263 / yr |
| 🇨🇦 CA Taxable | 25% | 9.47% | 6.67% | $947 / yr |
| 🇦🇺 Super (pension) | 15% | 10.74% | 7.94% | $1,074 / yr |
| 🇦🇺 AU Taxable | 30% | 8.84% | 6.04% | $884 / yr |
| 🇩🇪 DE Taxable | 26.375% | 9.30% | 6.50% | $930 / yr |
| 🇫🇷 FR Taxable | 30% | 8.84% | 6.04% | $884 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 RLYB Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 RLYB Dividend Payment Schedule
RLYB pays quarterly — 4 times per year. Next ex-div: TBD.
📊 RLYB vs Healthcare Benchmarks
How RLYB compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RLYB sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ RLYB Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-07-06 | 3,562 | $2.38 | $8.5K | ||
| M-Exempt | 2026-07-06 | 3,562 | $2.38 | $8.5K | ||
| Buy | 2026-05-19 | 200 | $13.80 | $2.8K | ||
| Buy | 2026-05-19 | 10,000 | $13.98 | $139.8K | ||
| Buy | 2026-05-18 | 6,009 | $13.98 | $84.0K | ||
| Buy | 2026-05-15 | 200 | $13.95 | $2.8K | ||
| Buy | 2026-05-15 | 100 | $13.80 | $1.4K | ||
| Buy | 2026-05-13 | 75,178 | $14.00 | $1.05M | ||
| Buy | 2026-05-13 | 4,081 | $13.80 | $56.3K | ||
| Buy | 2026-05-12 | 800 | $13.83 | $11.1K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Insiders are net buyers — historically a positive signal for dividend sustainability. Last purchase: 2026-05-19
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RLYB dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Rallybio Corporation (RLYB) is currently trading at $15.83, 90% below its 52-week high. The current dividend yield is 12.63% based on an annual payout of $2.00 per share.
RLYB (Rallybio Corporation) — 12.63% Dividend Yield Analysis
Rallybio Corporation (RLYB) is a healthcare stock currently trading at $15.83 with a dividend yield of 12.63%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (12.63%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.